Last reviewed · How we verify
PRP plasma rich platelets
PRP plasma rich platelets is a Small molecule drug developed by Anita Syla Lokaj. It is currently in Phase 1 development. Also known as: PRP.
Platelet-rich plasma (PRP) is a treatment that involves harvesting and preparing a patient's own platelets, which are then used to supplement various medical procedures, including perianal surgery and skin grafting. PRP has been studied in clinical trials for its potential to reduce pain at skin graft donor sites and treat complications related to skin grafts, such as rejection and detachment.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | PRP plasma rich platelets |
|---|---|
| Also known as | PRP |
| Sponsor | Anita Syla Lokaj |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PRP Injection Into the Sacroiliac Joint After Ipsilateral THA: Effects on Early Recovery and Function (SIJ-THA Randomized Trial) (NA)
- Thumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection (PHASE2)
- PRP as Adjuvant Treatment to CTR for Severe CTS Tunnel Syndrome (NA)
- Identification of Responders to Platelet-Rich Plasma (PRP) Injections in Lateral Elbow Epicondylalgia
- Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage. (PHASE2)
- Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases (PHASE1, PHASE2)
- Pilot Exploration of Platelet Characterization of Platelet Rich Plasma Created by Two Different Systems (PHASE4)
- Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PRP plasma rich platelets CI brief — competitive landscape report
- PRP plasma rich platelets updates RSS · CI watch RSS
- Anita Syla Lokaj portfolio CI
Frequently asked questions about PRP plasma rich platelets
What is PRP plasma rich platelets?
Who makes PRP plasma rich platelets?
Is PRP plasma rich platelets also known as anything else?
What development phase is PRP plasma rich platelets in?
Related
- Manufacturer: Anita Syla Lokaj — full pipeline
- Also known as: PRP
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing